WILFRED I. CARNEY JR., MD

Plain English
This study looked at a substance called TIMP-1 in the blood of 362 patients with advanced prostate cancer that does not respond to hormone treatment. The researchers found that higher levels of TIMP-1 were linked to quicker death: patients with low levels lived about 43 months, while those with high levels survived only about 19 months. This is important because it means that checking TIMP-1 levels could help doctors better predict how long patients with this type of cancer might live. Who this helps: This helps patients and doctors by offering a tool to evaluate cancer progression.

Plain English
This study looked at how levels of a protein called HER2 in the blood affected the outcomes for 138 breast cancer patients whose tumors were HER2-positive and who were treated with a drug called lapatinib. The researchers found that 79% of patients had high levels of HER2 at the start. Patients who had a drop in their HER2 levels during treatment experienced better results, meaning they responded well to the drug and lived longer without the cancer worsening; specifically, those with a significant drop had improved response rates and longer progression-free survival compared to those with rising levels. Who this helps: This helps breast cancer patients and their doctors in making treatment decisions.

Plain English
This study looked at a substance called TIMP-1 in the blood of 55 patients newly diagnosed with multiple myeloma. Researchers found that 47% of these patients had high levels of TIMP-1, which was linked to more severe bone damage and poorer survival rates. Specifically, higher TIMP-1 levels indicated that patients were more likely to have advanced disease and had a survival hazard ratio of 1.003, meaning their risk of death increased with higher TIMP-1 levels. Who this helps: This information helps doctors better predict outcomes for multiple myeloma patients and tailor their treatments accordingly.

Plain English
Researchers analyzed the levels of a protein called carbonic anhydrase IX (CAIX) in the blood of 37 patients with ovarian cancer to see if it could predict how well they would respond to treatment. They found that the CAIX levels remained mostly unchanged during treatment, ranging from 30 to 1687 pg/mL, and did not correlate with the patients' survival or treatment outcomes. In contrast, another marker, CA-125, showed significant decreases after surgery and during chemotherapy. Who this helps: This research helps doctors understand that CAIX is not useful for tracking treatment effectiveness in ovarian cancer patients.

Plain English
This study investigated the levels of two proteins, TIMP-1 and VEGF-165, in the blood of women with ovarian cancer during their first treatment. It found that higher levels of these proteins after chemotherapy were linked to shorter overall survival and worse progression-free survival; specifically, high CA-125 levels were associated with a risk of shorter survival (p = 0.002), while TIMP-1 (p = 0.007) and VEGF-165 (p = 0.02) also indicated poorer outcomes. Understanding these markers helps doctors predict which patients may have a worse prognosis, allowing for better treatment planning. Who this helps: This helps patients and their doctors by identifying those at higher risk for poor outcomes.

Plain English
This study looked at the presence of circulating tumor cells (CTCs) in the blood of women with a specific type of advanced breast cancer called HER-2 positive metastatic breast cancer, who were receiving treatment with trastuzumab and chemotherapy. The researchers found that having CTCs at the first follow-up check was linked to worsening disease, while a drop in certain markers, like HER-2/ECD, during treatment was linked to better outcomes. These findings matter because they show that tracking CTCs and related markers can help doctors understand how well treatment is working. Who this helps: This helps patients and their doctors by providing better ways to monitor treatment effectiveness.

Plain English
This study examined how high levels of a protein called TIMP-1 in the blood affect the treatment responses of breast cancer patients. Out of 522 patients studied, 23% had elevated TIMP-1 levels, and these patients showed a lower response to treatments: only 19.2% responded to letrozole compared to 30.6% with normal levels, and their overall survival time was also shorter at 20.3 months versus 35.8 months. This matters because knowing a patient’s TIMP-1 level can help doctors predict how well they will respond to treatments, and targeting TIMP-1 along with another protein called HER-2 might improve outcomes for some patients. Who this helps: This helps breast cancer patients and their doctors by providing more insight into treatment options.

Plain English
This study looked at a protein called tissue inhibitor of metalloproteinase-1 (TIMP-1) in women with metastatic breast cancer to see how its levels affected treatment outcomes. Researchers found that 19 out of 251 patients (7.6%) had high TIMP-1 levels, which were linked to a lower chance of benefiting from treatment (16% vs 42% for those with normal levels), shorter time before the cancer progressed (84 days vs 174 days), and much shorter overall survival (141 days vs 860 days). This is important because measuring TIMP-1 levels could help doctors predict which patients might not respond well to hormone therapy, allowing for more personalized treatment plans. Who this helps: This helps doctors and patients with metastatic breast cancer understand treatment options better.

Plain English
This research discusses the difficulties that the healthcare industry faces in using new biomarker discoveries to improve drug development. For example, Dr. Walter Carney, who helped identify a specific protein called HER2/neu in women with metastatic breast cancer, highlights that although there are advancements in biomarker research, it hasn't been fully integrated into treatment. This is important because effectively using these biomarkers could lead to more targeted and effective therapies for patients. Who this helps: Patients with specific types of cancer.

Plain English
This study looked at how certain medications and fluids affect blood flow through vein grafts during lower limb surgery. Researchers tested five different treatments on 60 patients and found that phenylephrine significantly increased vein graft flow from 39.5 to 58.9 mL/min, while epinephrine actually reduced flow in some patients. These findings are important because they reveal that not all treatments improve blood flow in vein grafts, which can impact surgical outcomes. Who this helps: This helps doctors and surgeons make better decisions about how to manage blood flow during surgeries involving vein grafts.

Plain English
This study looked at a protein called epidermal growth factor receptor (EGFR) in patients with metastatic breast cancer to see how it affects their survival. Researchers found that patients with low EGFR levels had a median survival of 23.3 months, compared to 30.9 months for those with normal levels. This matters because it helps identify patients who may not respond as well to treatment and have a shorter survival time. Who this helps: This research benefits doctors and patients by improving the way they assess treatment options and outcomes.

Plain English
This study looked at the levels of a protein called HER-2 in blood and tissue samples from 157 breast cancer patients. Researchers found that the average level of HER-2 in the blood was about 12.5 ng/ml and that 13.4% of the samples had levels above 15 ng/ml, which is significant. These findings help doctors understand which patients have more aggressive tumors based on HER-2 levels, especially when tumor tissue is not available for testing. Who this helps: This helps patients and doctors by providing insight into tumor aggressiveness and guiding treatment decisions.

Plain English
This study looked at breast cancer patients who initially tested negative for a protein called HER-2/neu when starting hormone therapy. Researchers found that 26% of these patients converted to a positive HER-2/neu status when their disease progressed, which is associated with shorter survival. Specifically, those who converted had a significantly reduced survival time compared to those who remained negative. Who this helps: This research benefits breast cancer patients and their doctors by highlighting a new marker that indicates a risk for worse outcomes during treatment.

Plain English
This study looked at how changes in serum HER-2/neu levels affect survival in patients with metastatic breast cancer. Researchers analyzed blood samples from 286 patients and found that 37% had low HER-2/neu levels, while 25% had continuously high levels. Patients with consistently high levels had a much shorter survival time, emphasizing that regular monitoring of these levels can provide important information about a patient’s prognosis and treatment options. Who this helps: This helps patients with metastatic breast cancer and their doctors make informed decisions about treatment.

Plain English
This study examined the levels of a specific protein called HER-2/neu in the blood of 33 women with metastatic breast cancer who were treated with trastuzumab. It found that women with lower levels of this protein (30 ng/ml or less) had a longer time before their cancer progressed, specifically an average of 266 days, compared to those with higher levels. Monitoring HER-2/neu levels during treatment can give important insights that help doctors make better treatment decisions. Who this helps: This benefits patients with metastatic breast cancer and their doctors.

Plain English
This study looked at how levels of a protein called HER-2/neu in the blood affect how well metastatic breast cancer patients respond to two treatments: letrozole and tamoxifen. Out of 562 patients, those with normal HER-2/neu levels had a much better response to letrozole, with 39% showing benefits compared to just 26% with tamoxifen. In contrast, for patients with elevated HER-2/neu levels, the difference in response rates was minimal, but there was a trend suggesting letrozole still offered some advantages in terms of how long patients could avoid their cancer worsening. Who this helps: This research helps breast cancer patients and their doctors choose the most effective treatment based on HER-2/neu levels.

Plain English
This study examined p53, a protein that can indicate cancer, in tissue samples from 115 patients with colorectal conditions, including tumors. They found that 62.5% of cancer patients had high levels of p53, compared to just 23.7% of those with benign growths and 3.1% of healthy controls. This precise measurement of p53 levels was linked to survival outcomes, showing that patients with higher levels had shorter survival times. Who this helps: This research benefits patients with colorectal cancer by providing clearer survival predictions and guiding treatment choices.

Plain English
This study looked at how high levels of a protein called HER-2/neu in the blood affect the success of hormone therapy in women with advanced breast cancer. They found that among 719 patients, 30% had high HER-2/neu levels. Patients with elevated levels responded to treatment only 23% of the time, compared to a 45% response rate in those with normal levels, and their survival was shorter—17.2 months versus 29.6 months for those without high levels. Who this helps: This information helps doctors better understand which breast cancer patients may not respond well to hormone therapy, guiding more personalized treatment plans.

Plain English
This study looked at two blood markers, HER-2/neu and CA 15-3, in patients with advanced breast cancer to understand their connection to cancer progression and outcomes. They found that 30% of patients had high levels of HER-2/neu, while 60% had high levels of CA 15-3. Patients with increased HER-2/neu had shorter survival rates (about 513 days) compared to those with normal levels (about 869 days), indicating that high levels of HER-2/neu are related to poorer outcomes. Who this helps: This research benefits doctors and patients by providing insights into cancer progression and treatment responses.

Plain English
This study looked at how levels of a specific protein (NRP) in the blood can predict whether women with advanced breast cancer will respond to hormone therapy. Among the 94 patients examined, 34% had high levels of NRP, and only 9% of those patients benefited from the treatment with droloxifene, compared to 56% of patients with normal NRP levels. This information is important because it can help doctors decide who is unlikely to benefit from hormone therapy, potentially leading to more personalized treatment plans. Who this helps: Patients with advanced breast cancer.

Plain English
This study looked at breast cancer tumors to see how a protein called Bcl-2 relates to hormone receptors (like estrogen) and DNA damage. In 37 breast cancer samples, most low-grade tumors (96.4%) had high levels of Bcl-2, while high-grade tumors (100%) did not, showing a clear connection between Bcl-2 presence and tumor grade (p < 0.001). This matters because high Bcl-2 levels can prevent cell death in lower-grade cancers, potentially affecting treatment strategies. Who this helps: Patients with breast cancer, particularly those with low-grade tumors.

Plain English
This study looked at how certain changes in the p53 protein, caused by exposure to vinyl chloride (a chemical linked to liver cancer), affect its structure. The researchers found that two specific mutations in the p53 gene led to noticeable changes in the protein's shape, making parts of it more exposed, which could help in detecting cancer. Importantly, they discovered that patients with these mutations had detectable mutant p53 proteins in their tumors and blood, while those without mutations did not. Who this helps: This helps doctors and patients by providing a way to identify specific cancer types linked to vinyl chloride exposure.

Plain English
This study looked at specific proteins in the blood of patients with asbestosis, a lung condition caused by exposure to asbestos, to see how these proteins are linked to the presence of cancer. They found that 36% of asbestosis patients with cancer had higher levels of the protein TGF-alpha, while 38% of those without cancer also had higher levels. Although there were noticeable differences in protein levels among the groups, the results were not statistically significant. Who this helps: This information can help doctors better understand the potential cancer risk in patients with asbestosis.

Plain English
This study looked at levels of a specific protein called p53 in the blood of 23 lung cancer patients, comparing them to healthy individuals and people with non-cancer lung issues. The researchers found that the average p53 levels in lung cancer patients were higher (0.55 ng/mL) than in both control groups, but only a few patients had levels significantly above normal. This is important because it shows that measuring p53 in the blood may help identify some lung cancer cases that have specific changes in the tumor. Who this helps: Patients with lung cancer might benefit from this approach as it could help with diagnosis.

Plain English
This study looked at a specific type of breast cancer cells, called SK-BR-3, which produce a protein known as p185. The researchers found that these cells release a portion of this protein, called p105, into their surroundings, which could be important in understanding how the cancer develops and might help in detecting the disease. They discovered that p105 has a similar structure to p185 and is produced through a process that alters the original protein. Who this helps: This benefits patients by potentially improving cancer detection and treatment options.

Plain English
This study focused on creating and understanding a specific antibody (89E5) that targets proteins commonly found in epithelial tumors, which include cancers like breast and lung cancer. Researchers discovered that this antibody could identify tumor cells and that they successfully developed a human version of it (PA1) that worked similarly. Both antibodies recognized the same tumor markers, highlighting the potential for using human antibodies in cancer treatment. Who this helps: This research benefits cancer patients by advancing the development of targeted therapies.

Plain English
This study focused on measuring IgG and IgM antibodies to the cytomegalovirus (CMV) in both healthy people and those with weakened immune systems. Researchers found that IgM antibodies were specifically linked to active CMV infections, especially in patients with mononucleosis, where heightened levels were noted during virus activity. In cardiac transplant patients, low IgM levels during severe infections suggested that insufficient IgM might be tied to worse disease outcomes. Who this helps: This research benefits patients with CMV infections, especially those who are immunocompromised, such as organ transplant recipients.